

SAFETY ASSESSMENT OF AQUEOUS EXTRACT OF *Garcinia Kola* (LINN) SEEDS THROUGH MICROSTRUCTURAL EFFECTS ON HIPPOCAMPUS, KIDNEY AND BIOCHEMICAL INDICES IN ADULT MALE RATS

Adeosun, Isaac O¹. Obajuluwa, Adejoke O^{2*}. Afolayan, Taye A². Okiki, Pius A², Obajuluwa, Tiwalola M³. Sobajo, Oguntope A². Asoso, Oluwakemi S². Obagaye, Olubunmi V²

¹Department of Physiology, College of Health Sciences, Afe Babalola University.

²Department of Biological Sciences, Afe Babalola University Ado Ekiti.

³Department of Media and Communication Studies, Afe Babalola University Ado Ekiti.

*ibitayoao@abuad.edu.ng; joke_ibitayo@yahoo.com

Abstract

The knowledge of the pharmacokinetic properties of *Garcinia kola* seeds has led to its increased consumption in places where it is indigenous thereby making its safety assessment at high doses a necessity. The study was carried out using twenty five male adult wistar which were assigned into five groups (n=5). Negative control group (I) received 25 ml/kg b.w distilled water, Group II (2 mg/kg Furosemide (reference drug control group) and other groups (III –V) served as the experimental groups for aqueous extract of *Garcinia kola* seeds-AEGKS1 (400 mg/kg b.w), AEGKS2 (400 mg/kg b.w), AEGKS3 (800 mg/kg b.w). Baseline and post 28-day AEGKS administration effects were determined (for the experimental and control groups) through serum and tissue (kidney) alanine/aspartate aminotransferases activity (AST/ALT) levels and p-values less than 0.05 were considered statistically significant using standard methods. Also, its nephrotoxic and neurotoxic potentials were ascertained through microstructural findings using the H&E technique. Biochemical indices of toxicity in the kidney and serum of rats were correlated with changes in their serum ALT/AST and homogenized kidney samples. Analysis of variance showed significantly reduced ALT/AST in AEGKS2 and AEGKS3 rats' serum when compared with the reference drug group and negative control while tissue AST/ALT were significantly reduced in the AEGKS1 and AEGKS2 when compared with other experimental groups. No significant microstructural changes were found in the hippocampus of rats' brain except in the AEGKS3 group while interstitial nephritis was observed in the kidneys' of rats from standard

Keywords: *Garcinia kola*, Kidney, Hippocampus, Furosemide, neurotoxic, nephrotoxic

Introduction

Garcinia kola is consumed in large quantities especially in places where it is indigenous and relatively abundant^{1,2}. This phenomenon dates back to several centuries as medicinal plants and herbal remedies are believed to have no serious side effects and relatively safe^{3,4}. *Garcinia kola* plant has a popular acronym- "wonder" plant, among the South-Western Nigerian people because every part of it has been found to be of medical importance^{5,6}. It consists of fruits, leaves, roots, barks, stems and twigs etc. which have been reported to possess antibacterial activity, antidiabetic, antiviral and anti-hepatotoxicity potentials^{7,8} and are also used to prevent or relieve colic pains, cure head and chest colds among others based on its phytochemicals constituents. This includes oleoresin, tannin, saponins, alkaloids, and cardiac glycoside while others are; biflavonoids such as kolaflavonone, and 2 hydroxyflavonoids⁹. Also, the neuroprotective potential of *Garcinia* biflavonoid complex has been reported where it was shown to reverse cerebellar degeneration through modulation of neurochemical signaling pathways and stressor molecules that underlie Alzheimer diseases pathogenesis¹⁰. Kolaviron (isolated from seeds of *Garcinia kola*) has been shown to be hepatoprotective in both *in-vivo* and *in-vitro* models^{11,12,13} via its strong antioxidant properties which limits the oxidative conversion of amino acid by reactive oxygen species to other damaging fatty acid products¹⁴. *Garcinia kola* drug interactivity has also been tested in diverse studies and shown to have no drug metabolizing effects or interaction with orthodox medications^{15,16}. However, kolaviron interactivity with metabolites of amodiaquine¹² could increase coronary disease risk and also refutes its wholesomeness in non-interaction with orthodox medications findings. Results of findings by¹⁷ also suggests that ethanolic extracts *Garcinia kola* seeds at 200 mg/kg body weight alters oestrous cycle in rats, partly inhibits ovulation and may produce duration dependent teratogenicity in foetal rats. Although, *Garcinia kola* has been reported to possess aphrodisiac properties^{18,19}, sub-chronic studies of 250 mg/kg and 500 mg/kg indicated reduced appetite and suppressed spermatogenesis²⁰ and infertility²¹ in the animal models used. This suggests its prolonged

consumption in high quantities could promote deleterious effects on spermatogenesis and sperm cells.

Although, acetylcholinesterase (ACh) inhibition potential of *Garcinia kola* seeds extract (Kolaviron) provides an evidence for its therapeutic potential in the management of neurodegenerative disorders associated with disturbed cholinergic neurotransmitter systems²², its proper investigation for better understanding of the detailed mechanism is essential as this neurotransmitter (AChE) is critical in memory and cognition functions. Hence, in spite of their relatively safe pharmacological properties, there is a need to authenticate safety and toxicity alongside orthodox drugs to ascertain safe dose levels in order to prevent tissue damage among others. This makes it imperative for further research as few existing literatures reports the effects of high dose levels of *Garcinia kola* which is important for safe dose limits and its standardization as a drug in treatment of diseases.

Methods

Experimental Design: Twenty five adult male Wistar rats weighing between 180 g and 220 g bred in the Animal House of Human Biology Department, Afe Babalola University were selected and used. They were acclimatized to laboratory conditions for two weeks before the commencement of the experiments and housed under standard laboratory conditions in plastic cages under a 12-h daylight cycle with free access to pelletized rat chow and water. Random distribution was done after acclimatization and rats were grouped into five [n=5]: Negative control [10 ml/kg body weight], Furosemide (20 mg/kg b.w, Standard), AEGKS1 (400 mg/kg b.w of AEGKS), AEGKS2 (600 mg/kg b.w of AEGKS), AEGKS3 (800 mg/kg b.w of AEGKS).

The treatment lasted for 28 days and all administration was done via oral gavage on a daily basis. Experimental procedures were in strict compliance with experimental animal care and use of laboratory animals in biomedical research regulation of the University.

Plant Materials: Fresh seeds of *Garcinia kola* were locally sourced and verified (FHI-109777). Dried *Garcinia kola* seeds (2kg) were washed and cut into smaller pieces with a sterile knife and aired dried at

room temperature (28 °C-30 °C) in a tray for three weeks. The dried *Garcinia kola* seeds were pulverized and extraction was carried out by soaking the sample in distilled water (1:2 wt./vol) for 48 h at room temperature [26 - 28 °C]. Filtrate from the resulting solution was done using Whatman no. 1 filter and later concentrated using the rotary evaporator at 37 °C. Forty gram of the aqueous extract of *Garcinia kola* seeds [GKS] was dissolved in 100 ml of distilled water to give a concentration of 0.4 g/ml and kept refrigerated(-4 °C) until use.

Experimental Controls: Furosemide (Mark Tianjin, China™) was obtained from Kanada Pharmaceutical Ltd, Ado-Ekiti, Nigeria which was used as the reference drug for the positive control group while the negative control group received distilled water only.

Determination of Biochemical Parameters: Serum and renal AST / ALT levels were determined both in the serum and the kidney homogenate of experimental rats for measure of hepatic and nephrotoxicity which was done according to the method of 23 which was determined using Erba Mannheim kits™. The kidneys were excised, blotted and weighed. A portion of the kidney (500 mg) was carefully removed and homogenized with Teflon homogenizer™ in ice-cold Tris-HCl buffer [pH 7.4].


Histomorphometric Analysis: The weights of the harvested tissues (kidney and brain) were documented for all groups using weighing balance. Small portions from the harvested kidneys and brain [hippocampus] were cut and fixed in 10% formaline in sterile plain bottles. Fixed tissues were thereafter sectioned (5 µm) and embedded in paraffin. Sections were stained using the Hematoxylin and Eosin [H&E] technique and examined under a light microscope [Olympus BX-51, Japan] by a pathologist. Light microscopic examination of multiple tissue sections from each organ in all groups were carried out as described by 24.

Statistical Analysis: Comparison between the mean values of variables(data) among the controls and the AEGKS dose groups was done using one-way analysis of variance [Graphpad Prism 5] and post hoc tests (Tukey multiple comparison) was used to identify the significance of pair wise comparison of mean values among the groups. Statistical

significance were considered at $p < 0.05$ as performed in all groups.

Results

Effect of AEGKS on serum AST and ALT Levels in male rats: AST and ALT levels assayed in the serum and tissues (liver) of experimental rats used in this study after 28 days AEGKS at different doses (400 mg/kg, 600 mg/kg and 800 mg/kg) are shown in Fig 1:








Fig 1: One way ANOVA of AEGKS on serum and tissue (liver) in male Wistar rats. (Data expressed as mean \pm S.E.M. n=5 (*= p<0.05 vs negative control; # = p<0.05 vs. Furosemide).

Administration of different doses of AEGKS significantly reduced serum AST when compared with the control and furosemide-treated groups, except the groups treated with 400 mg/kg mg which showed similar effect on serum AST with furosemide-treated group (Fig. 1A and 1B). Also, serum ALT and tissue AST were reduced in a dose-dependent manner in the AEGKS groups as seen in Fig. 1B and 1C. Consequently, tissue (kidney). ALT of rats in the AEGKS group was significantly lower than other groups except in AEGKS3 rats Fig. 1D while the lowest ALT activity was seen in the AEGKS2 (600 mg/kg b.w) group.


Histomorphometric analysis of AEGKS doses on rats' brain [hippocampus] using H & E Technique (X400): The microstructural effects of AEGKS in the hippocampus of experimental rats are shown in Fig 2:




(A) Group I: Distilled Water(Negative Control)




(B) Group II: Furosemide(Positive Control)



(C) Group III: AEGKS 1(400mg/kg)



(D) Group IV: AEGKS 2(600mg/kg)




(E) Group V: AEGKS 3 (800mg/kg)


Fig. 2: Photomicrograph section of the hippocampus in negative control rats (A) show distinct region of the hippocampus (CA1-CA4 and dentate gyrus GD). The cyto-architecture of the neurons, glia cells (granular and pyramidal cells) capillaries (arrow) and ventricles appear

essentially normal and unremarkable. No inflammatory response observed. (B-D) the cytoarchitecture of the neurons, neural parenchyma, glia cells (granular and pyramidal cells) and capillaries appear essentially normal and unremarkable in photomicrographs shows section of the hippocampus furosemide, AEGKS 1 and AEGKS 2.No inflammatory response observed. (E) photomicrograph section of AEGKS3 shows peri-capillary leukocytes adhesion (arrow).


Histomorphometric analysis of AEGKS doses on rats' kidney using H & E Technique (X400):




(A) Group I: Distilled Water(Negative Control)




(B) Group II: Furosemide(Positive Control)



(C) Group III: AEGKS 1 (400mg/kg)



(D) Group IV: AEGKS2 (600mg/kg)



(E) Group V: AEGKS3 (800mg/kg)

Fig. 3: Photomicrograph of negative control rats' kidney (A) shows renal corpuscle composed of intact glomeruli (CG), well defined bowman's space. The renal tubules are lined by regular epithelium and the interstitium is free from collection and inflammatory cells. Photomicrograph of Furosemide group (B) shows marked interstitial congestion (CG) and microangiopathy (arrow head) while

the renal tubules appear unremarkable. Photomicrograph of AEGKS₁ (C) shows the renal corpuscle (arrow head) composed of the glomerulus (G), well defined bowman's space. The renal tubules are lined by regular epithelium, the interstitium is free from collection and inflammatory cells with widened urinary space (RT). Photomicrograph of AEGKS₂ (D) shows the renal corpuscle (arrow) composed of the glomerulus (G), well defined bowman's space. The renal tubules (RT) are lined by regular epithelium, the interstitium is free from collection and inflammatory cells. Photomicrograph of AEGKS₃ (E) shows marked interstitial congestion (star). The renal tubules appear unremarkable.

Discussion

Our present results showed a significant reduction in serum AST and ALT when compared with both the control and furosemide-treated groups, except the group treated with 400 mg/kg AEGKS₁. However, tissue ALT of this group was significantly altered when compared to control and furosemide-treated groups while the group treated with 800 mg/kg AEGKS was higher than other groups (Fig. 1D). The levels of the markers of AEGKS toxicity measured in the serum and kidneys of rats used for the study confirms it's non-invasive ability except at high doses such as observed in the AEGKS₃ (800 mg/kg) group.

Plasma/tissue AST or ALT are potent biomarkers of toxicity²⁵ and findings from this study exclusively reports *G. kola* non nephrotoxic potential even at a high dose of 600 mg/kg b.w when compared with the Furosemide (standard drug) group which showed significant drug side effects in the serum and renal biomarkers measured. This finding confirms *G. kola* non-invasive ability and anti-inflammatory properties at low doses which can be attributed to its rich biflavonoid complex and phytochemical constituents^{26, 27} with immense health benefits in cell and tissue integrity maintenance. Although, there was no indication of damage in the serum of rats in AEGKS₃ (800 mg/kg) their tissue ALT level was significantly higher than other groups indicating *G. kola* nephrotoxic potential at doses higher than 600 mg/kg. The histological findings revealed that there was no distortion of the cyto-architecture of the hippocampus of brains in both the control and the treated groups except the AEGKS₃ (800 mg/kg) which showed peri-capillary leukocytes adhesion indicating inflammatory response and neurotoxicity of AEGKS at doses higher than 600 mg/kg. The adhesion of leukocytes to

vascular endothelium is a hallmark of the inflammatory process²⁸ and the chronic activation of inflammatory processes is thought to drive oxidative stress and cellular necrosis which is indicated could be as a result of its caffeine content (0.607%) as reported²⁹. The tight junctions of the cerebral capillary endothelium form the highly restrictive blood-brain barrier and migration of leukocytes across this unique barrier may involve ligation of elements in addition to those of the fenestrated capillaries of the peripheral vascular system²⁸.

Although several findings have suggested its ameliorative potentials in management of neurodegenerative disorders^{10, 22} the findings of this study indicate the need to ascertain systemic levels of inflammatory markers and examine the cascade of inflammatory cytokines augmented expression and endothelial adhesion molecules in the proposed pharmacological interventions of *Garcinia kola* extracts and its other derivatives especially at prolonged exposure and high dose rates.

Significant microstructural changes were also observed in the kidneys of the furosemide (reference drug) group which showed marked interstitial glomeruli congestion (CG arrow in Fig 3) which indicates kidney injury³⁰ and depicts deterioration of renal function. Leukocyte interstitial infiltration in kidneys is linked to coordinated action of both kidney chemokine expression and leukocyte chemotaxis to kidney-expressed chemokines³¹. The pathological implications of microangiopathy observed in the kidneys of the furosemide group Fig. 3B) on the other hand reflects tissue responses to endothelial injury, including endothelial swelling and mesangiolysis in active lesions, and double contours of the basement membrane³²

These findings confirms the side effects of orthodox drugs used in treatment as observed in Furosemide group which might be as a result of the fact that the kidney is a vital organ for the elimination of therapeutic drugs and their metabolites³³ contrary to its non-neurotoxic effects observed in this study at the same dose (20 mg/kg b.w).

Consequently, AEGKS2 and AEGKS3 induced no nephrotoxic response as the histology of kidneys from rats in these groups revealed no significant alterations. This implies AEGKS safety at doses as high as 600 mg/kg b.w. However, AEGKS3 (800 mg/kg b.w) revealed marked interstitial congestion indicating nephrotoxic potential of AEGKS at doses higher than 600 mg/kg.

Conclusion

In a bid to evaluate nephrotoxic and neurotoxic potentials of *Garcinia kola* at high doses, this study examined the impact of varying doses of AEGKS (400 mg/kg b.w, 600 mg/kg b.w and 800 mg/kg b.w) in male Wistar rats against a standard drug used for inducing diuresis-*furosemide*. Based on this evaluation, excessive consumption of *Garcinia kola* popularly known as a safe and a “wonder plant/seed” with huge health benefits, should be discouraged as this could have significant side effects similar to orthodox drugs and should not be eaten arbitrarily.

Also, the results from this study suggests the safety of AEGKS at doses not more than 600 mg/kg b.w as higher doses could be neurotoxic and nephrotoxic.

Acknowledgments

We acknowledge the members of staff of Afe Babalola University Animal house where the animals for this study were kept and monitored.

References

1. Yakubu MT and Quadri AL: *Garcinia Kola* Seeds: Is the Aqueous Extract a True Aphrodisiac in Male Wistar Rats? *Afr J Tradit Complement Altern Med* 2012; 9(4): 530-535.
2. Ajayi SA, Ofusori DA, Ojo GB, Ayoka OA, Abayomi TA and Tijani AA: The microstructural effects of aqueous extract of *Garcinia kola* (Linn) on the hippocampus and cerebellum of malnourished mice. *Asian Pac J Trop Biomed* 2011; 1(4): 261-265.
3. Adeosun IO, Obajuluwa AO and Chigozie FC: Evaluation of the diuretic, serum and kidney electrolyte changes in wistar rats after aqueous extract of *Cola nitida* seeds administration. *Der Pharma Chemica* 2018; 10(2): 6-11
4. Ekene EN and Erhirhie EO: *Garcinia kola*: A Review of Its Ethnomedicinal, Chemical and Pharmacological Properties. *Int J Cur Res Rev* 2014; 06(11): 1-7.

5. Iwu MM, Igboko OA, Onwuchekwa UA and Okunji CO: Evaluation of the antihepatotoxic activity of the biflavonoids of *Garcinia kola* seed. *J Ethnopharmacol* 1987; 21(2): 127-38.
6. Iwu MM: Antihepatotoxic constituents of *Garcinia kola* seeds. *Experientia* 1985; 41: 699-700.
7. Farombi EO, Akanni OO and Emerole GO: Antioxidant and scavenging activity of flavonoid extract (Kolaviron) of *Garcinia kola* seeds. *Pharm Boil* 2002; 40: 107-116.
8. Akochere JF, Ndip RN, Chenwi EB, Ndip LM, Njock TE and Anang DN: Antibacterial effects *Zingiber officianel* and *Garcinia kola* on Respiratory tract pathogens. *East African Medical Journal* 2002; 79(11): 588-592.
9. Terashima K, Takaya Y and Niwa M: Powerful antioxidative agents based on garcinoic acid from *Garcinia kola*. *Bioorganic Med. Chem* 2002; 10(5): 1619-1625.
10. Ugbosanmi OOJ, Enaibe AT, Ogunrinola BU, Lewu KY, Tobechukwu SF, Akapa NA, Imam T, Ibrahim A, Gbadamosi A, Yawson IT and EO: Cerebellar molecular and cellular characterization in rat models of Alzheimer's disease: Neuroprotective Mechanisms of *Garcinia Biflavonoid Complex*. *Annals of Neuroscience* 2017; 24: 32-45.
11. Ijomone OM, Nwoha PU and Olaibi OK: Neuroprotective effects of kolaviron, a biflavonoid complex of *Garcinia kola*, on rats hippocampus against methamphetamine-induced neurotoxicity. *Maced J Med Sci* 2012; 5(1): 10-16.
12. Ajani EO, Shallie PD, Adegbesan BO, Salau BA and Akinpelu A: A study of hepatoprotective effect of *Garcinia kola* water extract in Amodiaquine and Artesunate treated rats. *Nigerian Journal of Health and Biomedical Sciences* 2008; 6(2): 9-15
13. Farombi EO, Adepoju BF and Ola-Davies OE: Chemoprevention of aflatoxin B1-induced genotoxicity and hepatic oxidative damage in rats by kolaviron, a natural biflavonoid of *Garcinia kola* seeds. *Eur J Cancer Prev* 2005; 14: 207-214.
14. Farombi EO: Mechanisms for the hepatoprotective action of kolaviron: Studies on hepatic enzymes, microsomal lipids and lipid peroxidation in carbon tetrachloride-treated rats. *Pharmacol Res* 2000; 42: 75-80.
15. Farombi EO, Tahnteng JG and Agbooola O: Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron, a *Garcinia kola* seed extract. *Food Chem. Toxicol* 2000; 38: 535-41.
16. Farombi EO, Alabi MC, Akuru TO. Kolaviron Modulates cellular redox status and impairment of membrane protein activities induced by potassium bromate (KBrO₃) in rats. *Pharm. Res.* 2002. 45(1): 63-68.
17. Akpantah, AO, Oremosu AA, Noronha CC, Ekanem TB and Okanlawon AO: Effects of *Garcinia kola* seed extract on ovulation, oestrous cycle and foetal development in cyclic female sprague - Dawley rats. *Nigerian Journal of Physiological Sciences* 2005; 20(1&2): 58-62.
18. Akintonwa A and Essien AR: Protective effect of *Garcinia kola* seed extract against paracetamol-induced hepatotoxicity in rats. *Journal of Ethnopharmacology* 1990; 29: 207-211
19. Ajibola AO and Satake M: Contribution to the phytochemistry of medicinal plants growing in Nigeria as reported in the 1979-1990 literature: A Preview. *African Journal of Pharmacy and Pharmacological Sciences* 1992; 22: 172-201.
20. Bukata BB: Pharmacological effects of methanolic extract of *Garcinia kola* (Heckel) seed on the reproductive profiles of some male experimental animals. PhD thesis Department of Pharmacology, University of Jos 2012.

21. Mesembe OE, Asuquo OR, Fischer VA, Udoaffah GU, Mfem CC and Kalu NN: Influence of long-term ingestion of *Garcinia kola* seed diet on sperm count, sperm motility, and fertility in the wistar rat. *Journal of Health, Medicine and Nursing* 2013; 1: 20-22.
22. Ijomone OM and Obi AU: Kolaviron, isolated from *Garcinia kola*, inhibits acetylcholinesterase activities in the hippocampus and striatum of wistar rats. *Annals of Neurosciences* 2013; 20(2): 42-46.
23. Tietz NW, Prude EL and Sirgard – Anderson O: *Textbook of Clinical Chemistry*. ed. Burtis C.A. and Ashwood E.R. pp 1354 –1374. W.B. Saunders Company, London 1994.
24. Ojo GB, Nwoha PU, Ofusori DA, Ajayi SA, Odukoya SA and Ukwenya VO: Microanatomical effects of ethanolic extract of *Garcinia kola* on the Stomach mucosa of adult wistar rats. *Afr. J. Trad. CAM* 2010; 7(1): 47-52
25. Wang CS, Chang TT, Yao WJ, Wang ST and Chou P: Impact of increasing alanine aminotransferase levels within normal range on incident diabetes. *J Formos Med Assoc* 2012; 111: 201-8.
26. Olaleye SB and Farombi EO: Attenuation of indomethacin- and HCl/ethanol-induced oxidative gastric mucosa damage in rats by kolaviron, a natural biflavonoid of *Garcinia kola* seed. *Phytother Res* 2006; 20: 14-20.
27. Farombi EO, Adedara IA, Ajayi BO, Ayepola OR and Egbeme EE: Kolaviron, a natural antioxidant and anti-inflammatory phytochemical prevents dextran sulphate sodium-induced colitis in rats. *Basic Clin Pharmacol Toxicol* 2013; 113: 49-55.
28. Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. *Pharmacol Ther.* 2015;147:123-135.
29. Mazi EA, Okoronkwo KA and Ibe UK: Physico-Chemical and Nutritive Properties of Bitter Kola (*Garcinia kola*). *J Nutr Food Sci* 2013; 3: 218.
30. Perry HM and Okusa MD: *Clinical Practice : Mini-Review Nephron* 2016;134:167-171.
31. Peralta AL, Mathian A, Tran T, Delbos L, Durand-Gasselín D, Berrebi M, Peuchmaur JC, Emilie D and Koutouzov S: Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. *Kidney Int.* 2008.73(2);172-80.
32. Brocklebank V, Wood KM and Kavanagh D: Thrombotic microangiopathy and the Kidney. *Clin J Am Soc Nephrol* 2018; 13: 300-317.
33. Yin J and Wang J: Renal drug transporters and their significance in drug–drug interactions. *Acta Pharm Sin B* 2016; 6(5): 363-373.